We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

NGM Biopharmaceuticals Inc (NGM) USD0.001

Sell:$18.13 Buy:$18.15 Change: $0.09 (0.49%)
Market closed |  Prices as at close on 7 December 2021 | Switch to live prices |
Change: $0.09 (0.49%)
Market closed |  Prices as at close on 7 December 2021 | Switch to live prices |
Change: $0.09 (0.49%)
Market closed |  Prices as at close on 7 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

NGM Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying liver and metabolic diseases, retinal diseases and cancer. The Company’s product candidates include Aldafermin, MK-3655, NGM621, NGM120, NGM707 and NGM438. Aldafermin is an engineered variant of the human hormone FGF19, which the Company is developing treatment for non-alcoholic steatohepatitis (NASH). MK-3655 is an agonistic antibody binding to fibroblast growth factor receptor 1c-beta-klotho, or FGFR1c/KLB and has the potential as an insulin sensitizer for the treatment of NASH. It is also developing NGM831 a novel antagonist antibody designed to block the interaction of ILT3 of fibronectin, as well as with other ligands.

Contact details

333 Oyster Point Blvd
United States
+1 (650) 2435555

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.40 billion
Shares in issue:
77.34 million
United States
US dollar

Key personnel

  • William Rieflin
    Executive Chairman of the Board of Directors
  • David Woodhouse
    Chief Executive Officer, Director
  • Jin-Long Chen
    Founder, Chief Scientific Officer, Director
  • Siobhan Mangini
    Chief Financial Officer
  • Valerie Pierce
    Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
  • Alex Depaoli
    Senior Vice President, Chief Translational Officer
  • Hsiao Lieu
    Senior Vice President, Chief Medical Officer
  • Wenyan Shen
    Senior Vice President - Biologics and CMC
  • Hui Tian
    Senior Vice President - Research
  • Marc Learned
    Vice President - Research Operations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.